Artiva Biotherapeutics, Inc Common Stock

Yahoo Finance • 7 days ago

Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating aut... Full story

Yahoo Finance • 2 months ago

AtaiBeckley names Michael Faerm as finance chief

AtaiBeckley names Michael Faerm as finance chief Proactive uses images sourced from Shutterstock AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it has appointed Michael Faerm as chief financial officer, effective March 9, 2026, as... Full story

Yahoo Finance • 4 months ago

After-Hours Gainers: Exicure Tops List With 72% Jump, Wave Life And Assembly Biosciences Advance

(RTTNews) - Biotechnology stocks saw notable movement in after-hours trading on Monday, with several companies posting strong gains. Below is a structured look at the key movers and the developments driving their performance. Exicure, Inc... Full story

Yahoo Finance • 5 months ago

Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease

32 patients with autoimmune disease treated with AlloNK plus anti-CD20 monoclonal antibody (mAb) as of October 1, 2025, data cutoff All patients received AlloNK as outpatients, and the majority were treated in community rheumatology trial... Full story

Yahoo Finance • 5 months ago

Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Over 100 patients treated with AlloNK across autoimmune and oncology indications Refractory rheumatoid arthritis (RA) prioritized as lead indication following FDA Fast Track Designation for AlloNK®, the first known therapy within the emer... Full story

Yahoo Finance • 5 months ago

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November

SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) --  Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating au... Full story

Yahoo Finance • 6 months ago

3 Promising Penny Stocks With Market Caps Under $200M

As major U.S. stock indexes reach new records, driven by anticipation of Federal Reserve decisions and tech earnings, the market continues to capture investor attention with its dynamic shifts. Amidst these developments, penny stocks remai... Full story

Yahoo Finance • 6 months ago

Top Midday Gainers

Rani Therapeutics (RANI) said on Friday that it signed a collaboration and licensing agreement value PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 6 months ago

Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update

Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK in refractory RA, representing the first drug candidate in the deep B-cell depleting category... Full story

Yahoo Finance • 8 months ago

Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025

SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating aut... Full story

Yahoo Finance • 10 months ago

ArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair

PRINCETON, N.J.--(BUSINESS WIRE)--ArrePath, a company applying its proprietary artificial intelligence and machine learning platform together with deep R&D technical expertise to address the challenge of best-in-class antibacterial drug di... Full story

Yahoo Finance • 11 months ago

Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating auto... Full story

Yahoo Finance • 11 months ago

Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

64% (9/14) complete response rate with AlloNK + rituximab in heavily pretreated patients that were naïve to prior CAR-T cell therapy, in line with approved auto-CAR-T therapies in aggressive B-NHL Median duration of response for AlloNK +... Full story

Yahoo Finance • last year

Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating au... Full story

Yahoo Finance • last year

Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating au... Full story

Yahoo Finance • last year

Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Initial data for AlloNK® from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented at a medical conference in 2025 Str... Full story

Yahoo Finance • last year

Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating aut... Full story

Yahoo Finance • last year

Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating aut... Full story